<p>This is a summary of the European public assessment report (EPAR) for Zoledronic acid Mylan. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zoledronic acid Mylan.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><ul><li>Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone;</li> <li>treatment of adult patients with tumour-induced hypercalcaemia (TIH).</li> </ul></div>
Therapeutic Area (MeSH)
ATC Code
M05BA08
ATC Item
N/A
Pharmacotherapeutic Group
Drugs for treatment of bone diseases
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| zoledronic acid | N/A | zoledronic acid |
EMA Name
Zoledronic acid Mylan
Medicine Name
Zoledronic acid Mylan
Aliases
N/ANo risk management plan link.
